OncoMatch/Clinical Trials/NCT07408635
IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
Is NCT07408635 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies IBI363 + Chemotherapy for unresectable stage iii non-small cell lung cancer.
Treatment: IBI363 + Chemotherapy — This study is a single-arm, phase II clinical trial evaluating the safety and efficacy of IBI363 combined with chemotherapy as a neoadjuvant treatment of non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR active mutation
Non-squamous and squamous NSCLC with EGFR active mutation positive ... are excluded
Required: ALK rearrangement
Non-squamous and squamous NSCLC with ... ALK rearrangement ... are excluded
Disease stage
Required: Stage III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer treatment
Lab requirements
Blood counts
anc count ≥ 1.5 × 10⁹/l; platelet count ≥ 100 × 10⁹/l; hemoglobin ≥ 90 g/l
Kidney function
serum cr ≤ 1.5 times of upper limit of normal (uln) or calculated creatinine clearance (clcr) ≥ 50 ml/min
Liver function
total bilirubin ≤ 1.5 × uln (≤ 3 × uln in gilbert's syndrome); ast and alt ≤ 2.5 × uln
Cardiac function
left ventricular ejection fraction (lvef) ≥ 50 %
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07408635 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR active mutation is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK rearrangement is a required biomarker for enrollment.
What disease stage is eligible?
Stage III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify